vaayaa.com
Healthcare 1 min read

FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia

May 01, 2026

The U.S. Food and Drug Administration today approved an expanded use for Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat agitation associated with dementia due to Alzheimer’s disease in adults.

Read full article on FDA Press Releases →

Source: FDA Press Releases — US Government, Public Domain

More in Healthcare

What Pennsylvania’s AI chatbot lawsuit teaches us about the psychology behind medical trust The Conversation Health · 2 min World Cup creates perfect conditions for infectious diseases to spread – here are the biggest threats health experts are watching for The Conversation Health · 2 min FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose FDA Press Releases · 1 min Summer between high school graduation and college is a critical time for preventing risky behaviors – here’s how parents can play a key role The Conversation Health · 2 min